ProShare Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History

ProShare Advisors’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-11,836	Closed	-$38.2K	–	2112
2025 Q1	$38.2K	Sell	11,836 -4,533	-28%	-$21.4K	﹤0.01%	1981
2024 Q4	$91.2K	Buy	16,369 +3,783	+30%	+$29.7K	﹤0.01%	2089
2024 Q3	$136K	Buy	+12,586	New	+$209K	﹤0.01%	1830
2024 Q2	–	Sell	-10,788	Closed	-$344K	–	1901
2024 Q1	$344K	Buy	+10,788	New	+$275K	﹤0.01%	1336
2022 Q1	–	Sell	-10,626	Closed	-$233K	–	2230
2021 Q4	$233K	Buy	+10,626	New	+$260K	﹤0.01%	1935

Other funds holding FDMT

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ProShare Advisors's FDMT Position: Q2 2025 in Review

ProShare Advisors sold out of 4D Molecular Therapeutics (FDMT) in Q2 2025, closing a stake of 11,836 shares — an estimated $38.2K sold.

ProShare Advisors first reported a position in FDMT in Q4 2021 and held it in 5 quarters. The position peaked at $344K in Q1 2024. 120 funds tracked by Wall St. Rank hold FDMT as of Q2 2025.

ProShare Advisors reported no remaining 4D Molecular Therapeutics position as of Q2 2025 after selling out during the quarter.
ProShare Advisors sold 11,836 4D Molecular Therapeutics shares in Q2 2025, an estimated $38.2K.
ProShare Advisors first reported a position in 4D Molecular Therapeutics in Q4 2021 and held it in 5 quarters.
ProShare Advisors's 4D Molecular Therapeutics position peaked at $344K in Q1 2024.
120 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2025.

Based on ProShare Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.